

INTERNET ADDRESS: SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE. SUITE 2400 AUSTIN. TEXAS 78701

RECEIVED

DEC 0 4 2001

FILE: 10WA:031US

AUSTIN

SAN ANTONIO

DALLAS

NEW YORK

LOS ANGELES MINNEAPOLIS

LONDON

HONG KONG

October 29, 2001

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Comprissioner for Patents, Washington, DC 20231 on the date below:

October 29, 2001

Date

.. Highlander

Commissioner for Patents Washington, DC 20231

RE:

SN 09/872,852 "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" - Paul B. McCray, Jr., et al. (Client

Reference: URIF:MO-49)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C14).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

espectfully submitted,

Steven (1) Highlander Reg. No. 37,642

SLH/cmb

Encl: as noted

25087512.1

PATENT

DEC 0 3 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

if some incation of:

Paul B. McCray, Jr., et al.

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A

HIGHLY CATIONIC BETA-DEFENSIN

ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US/SLH

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 24231 on the date

October 29, 2001

below:

Date

Steven J. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Steven L. Highlander

Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

October 29, 2001

							Page 1	
Form PTO-1449 (modified)				1 7	Atty. Docket No.		Serial No.	
				IOWA:031U	JS/SLH	09/87	2,852	
Fet of	Patents a	nd Publications f	or Applicant's	Applicant			· ·	
્ય				Paul B. McC	Paul B. McCray, Jr., et al.			
_	DKMA II	ON DISCLOSURE	STATEMENT					
3 2001	(Use	several sheets if neces	ssarv)	_	Filing Date:		Group:	
MARKO		t Documents			June 1, 2001		1646	
MARKSO		Page 1	Foreig	n Patent Docume See Page 1	Patent Documents		Other Art See Page 1	
				Dec 1 uge 1		<u> </u>	ee Page 1	
			U.S. Pa	tent Docum	nents			
Exam.	Ref.	Document	Date	Name	Class	Sub	Filing Date of	
Init.	Des.	Number				Class	Арр.	
	<u> </u>							
			Foreign P	atent Docu	ments	**		
Exam.	Ref.	Document	Date	Country	Class	Sub	Translation	
Init.	Des.	Number				Class	Yes/No	
						<u> </u>		
	Other	Art (Includi	ng Autho	r, Title, Dat	e Pertin	ent Pag	ges, Etc.)	
Exam. Init.	Ref. Des.	Citation						
	C1	Gallo, et al., "Antimicrobial peptides: an emerging concept in cutaneous biology," J. Invest Dermatol, 111(5):739-743, 1998.						
	C2	Ganz and Lehrer, "Antimicrobial peptides of vertebrates," Current Opinions Immun, 10:41-44						
		1998.						
	C3	Hamil et al., "HE2β and HE2γ, new members of an epididymis-specific family of androgen-regulated proteins in the human," Endocrinology, 141(3): 1245-1253, 2000.						
	C4	Harder et al., "Short communication—Mapping of the gene encoding human β-Defensin-2 (DEFB2) to chromosome region 8p22-p23.1," Genomics, 46:472-475, 1997.						
	C5	Jia et al., "Discovery of new human β-defensins using a genomics-based approach," Gene, 263:211-218, 2001.						
	C6	Kirchhoff et al., cultures," Mol. R	:CD52 mRNA i	s modulated by an	drogens and	temperature	in epididymal ce	
	C7	Krull et al., "Region-specific variation of gene expression in the human epididymis as revealed by in situ hybridization with tissue-specific cDNAs," Mol. Reprod. Dev., 34:16-24, 1993.						
	C8	Liu et al., "Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFκB, c-fos/c-jun, and p53 proteins," Mol. Carcinog., 22:235-246, 1998.						

25066728.1

EXAMINER: DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

	\ '			rage.	2 01 2
	Form PTO-1449 (modified)		Atty. Docket No.	Serial No.	
			IOWA:031US/SLH	09/872,852	
OLE	eist of Patents and Publications for	Applicant's	Applicant		
/ 0	FORMATION DISCLOSURE S		Paul B. McCray, Jr., e	t al.	
DEC 0			Filing Date:	Group:	
THE THOENS	(Use several sheets if necessary	ary)	June 1, 2001	1646	
B.	U.S. Patent Documents	Foreign I	Patent Documents	Other Art	
CRAD	See Page 1	S	See Page 1	See Page 1	
TO ALC	See Page 1	S	See Page 1	See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation				
	C9	Mathews et al., "Production of β-defensin antimicrobial peptides by the oral mucosa and slivary glands," Infect Immun., 67(6):2740-2745, 1999.				
	C10	Nilsson et al., "Patient education for adults with chronic eczema," Dermatol Nurs, 11(2):117-122, 1999.				
	C11	Oren and Shai, "Mode of action of linear amphipathic α-helical antimicrobial peptides," Biopolymers, 47:451-463, 1998.				
	C12	Osterhoff et al., "Molecular cloning and characterization of a novel human sperm antigen (HE2) specifically expressed in the proximal epididymis," Biol Reprod, 50:516-525, 1994.				
	C13	Russell <i>et al.</i> , "Coordinate induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory mediators lipopolysaccharide and tumor necrosis factor alpha," <i>Infect Immun.</i> , 64(5):1565-1568, 1996.				
	Ç14	Singh et al., "Production of β-defensins by human airway epithelia," Proc. Natl. Acad. Sci USA., 95:14961-14966, 1998.				

25066728.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERÊNCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.